Infliximab for refractory ulcerative proctitis

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 11, 2010, Pages 1178-1185

  Bouguen, G ^a   Roblin, X ^b   Bourreille, A ^c   Feier, L ^d   Filippi, J ^e   Nancey, S ^f   Bretagne, J F ^a   FlouriE B ^f   HEbuterne X ^e   Bigard, M A ^d   Siproudhis, L ^a   Peyrin Biroulet, L ^d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; AGED; ARTICLE; BURSITIS; CLINICAL ARTICLE; COLON MUCOSA; DIVERTICULITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; PSORIASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77951779075     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04293.x     Document Type: Article

References (36)

1. Bjornsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland, 1980-89. A retrospective nationwide epidemiologic study. Scand J Gastroenterol 1998 33 : 71 7.
2. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009 44 : 431 440.
3. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 1994 35 : 1433 1438.
4. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006 12 : 543 550.
5. Moum B, Vatn MH, Ekbom A, et al. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 1996 31 : 362 366.
6. Pagenault M, Tron I, Alexandre JL, et al. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif]. Gastroenterol Clin Biol 1997 21 : 483 490.
7. Ayres RC, Gillen CD, Walmsley RS, et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996 8 : 555 558.
8. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000 95 : 469 473.
9. Stewenius J, Adnerhill I, Ekelund GR, et al. Risk of relapse in new cases of ulcerative colitis and indeterminate colitis. Dis Colon Rectum 1996 39 : 1019 1025.
10. Regueiro M, Loftus EV Jr., Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006 12 : 972 978.
11. Travis SPL, Stange EF, Lemann M, et al. European evidence-based Consensus on themanagement of ulcerative colitis: current management. J Crohn's Colitis 2008 2 : 24 62.
12. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986 27 : 1210 1212.
13. Regueiro M, Loftus EV Jr., Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006 12 : 979 994.
14. Turunen U, Farkkila MA, Valtonen V. Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 1999 117 : 282 283. (Pubitemid 29297652)
15. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998 115 : 1072 1078.
16. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporin enemas for midly to moderately active left-sided ulcerative colitis. Gastroenterology 1994 106 : 1429 1435.
17. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996 110 : 1416 1421.
18. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55 : 47 53.
19. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000 95 : 1201 1207.
20. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 55 : 1255 1262.
21. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002 16 : 1751 1759.
22. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009 15 : 193 198.
23. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008 28 : 1214 1220.
24. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005 100 : 1539 1546.
25. Bloom S, Kiilerich S, Lassen MR, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2004 19 : 871 878.
26. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005 54 : 242 249.
27. Thomas GA, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996 8 : 769 776.
28. Bolin TD, Wong S, Crouch R, et al. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol 2009 104 : 2476 2482.
29. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
30. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008 2 : 219 225.
31. Molnar T, Farkas K, Nagy F, et al. Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. Am J Gastroenterol 2009 104 : 1857 1858.
32. Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004 10 : 731 736.
33. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006 55 : 749 753.
34. Colombel JF, Ricart E, Loftus EV Jr., et al. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003 98 : 2239 2244.
35. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009 58 : 492 500.
36. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007 13 : 123 128.